Rockwell Medical, Inc. (RMTI) | Investment Case

1. Company Snapshot

1.a. Company Description

Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally.The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores.It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers.

The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream.It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home.Its target customers include medium and small sized dialysis chains and independent dialysis centers.

Rockwell Medical, Inc.was incorporated in 1996 and is headquartered in Wixom, Michigan.

Show Full description

1.b. Last Insights on RMTI

Rockwell Medical's recent performance was negatively impacted by a quarterly loss of $0.05 per share, which lagged revenue estimates. The company's Q3 2025 earnings call revealed a loss, compared to earnings of $0.05 per share a year ago. Despite achieving profitability on an Adjusted EBITDA basis, the company faced challenges. Recent appointments, including Joe Dawson to the Board of Directors and Rashad Brown as Vice President, Manufacturing and Supply Chain, may help drive future growth.

1.c. Company Highlights

Last Price	0.93
Change Percentage	-1.38%
Open	0.92
Previous Close	0.94
Market Cap ( Millions)	37
Volume	145843
Year High	2.1
Year Low	0.78
M A 50	0.97
M A 200	1.07

FCF Yield	-3.29%
Dividend Yield	0.00%
ROE	-15.64%
Debt / Equity	33.73%
Net Debt / EBIDTA	999781.03%
Price To Book	0.99
Price Earnings Ratio	-6.87
Price To FCF	-30.41
Price To sales	0.53
EV / EBITDA	9983.19

2. Rockwell Medical 2025: Turning Volatility into Profitability

Rockwell Medical delivered net sales of $18.3 million in Q4 2025, a 26% drop YoY but 15% up from Q3, while gross profit surged 70% to $3.9 million. Adjusted EBITDA rebounded to $1 million, and the company posted a net loss of $600,000, a three‑fold improvement. Staff Analyst Mark Strobeck cited the company’s disciplined cost management as the key driver of margin resilience. The stock trades at a P/E of –6.75 and a P/B of 0.97, reflecting market expectations of continued turnaround.

Publication Date: Apr -13

                                    📋 Highlights
                                    Adjusted EBITDA Profitability::
                                                Achieved positive adjusted EBITDA of $1M in Q4 2025 and $300K for the full year 2025, marking the second consecutive year of profitability.
Strong Cash Position::
                                                Ended 2025 with $25,000,000 in cash, driven by positive Q4 operating cash flow and improved net loss ($600K vs. $1.8M in Q3 2025).
Gross Margin Expansion::
                                                Q4 2025 gross margin hit 21%, a 70% increase in gross profit ($3.9M) compared to Q3 2025 ($2.3M).
Customer Agreements Growth::
                                                Secured key partnerships including a 3-year deal with Concerto Renal Services and ongoing contracts with Fresenius, DaVita, and others.
2029 Long-Term Targets::
                                                Aims for $100M+ annual net sales, 30% gross margins, and $5M–$10M annual profitability, driven by at-home dialysis market expansion and product diversification.

                                

Revenue Dynamics

Q4 sales fell 26% from Q4 2024 due to a shift in the customer mix, yet the 15% quarter‑over‑quarter rise indicates emerging demand, particularly from new West Coast accounts and a multi‑year deal with Innovative Renal Care.

Gross Margin Expansion

Gross margin hit a historic 21% in Q4, up 70% from Q3, driven by higher‑margin product configurations for at‑home dialysis and efficient supply‑chain adjustments that trimmed cost of goods sold.

Adjusted EBITDA Resurgence

Adjusted EBITDA turned positive at $1 million in Q4 and $300,000 for the year, underscoring a return to profitability after two consecutive EBITDA‑positive quarters, with 2026 guidance of $1–$2 million.

Cash Flow and Liquidity

Positive cash flow from operations in Q4 generated $25 million in cash, a significant cushion that supports ongoing investments in the West Coast expansion and potential M&A opportunities.

Customer Portfolio Strength

Rockwell serves ~300 U.S. customers, including all five top dialysis providers, and supplies concentrates to 30+ countries, with strategic multi‑year agreements with DaVita, Fresenius, and DaVita’s forecasted volumes bolstering revenue stability.

At‑Home Dialysis Opportunity

The at‑home market is projected to capture 10% of dialysis volume; Rockwell’s product lines are already tailored for home use, positioning the company to capture this growing segment alongside commercial centers.

Forward‑Looking Outlook

Management expects 2026 adjusted EBITDA of $1–$2 million and aims for $100 million in annual sales by 2029, targeting 30% gross margins and $5–$10 million in profit through portfolio diversification.

Valuation Snapshot

With a P/E of –6.75 and a P/B of 0.97, the market prices in a turnaround narrative; EV/EBITDA remains high at 9,983.46, reflecting the company’s current loss profile but future upside potential.

3. NewsRoom

Rockwell Medical to Release First Quarter 2026 Results on Thursday, May 7, 2026

Apr -09

Source: businesswire.com

Rockwell Medical, Inc. (RMTI) Q4 2025 Earnings Call Transcript

Mar -26

Source: seekingalpha.com

Rockwell Medical (RMTI) Reports Q4 Loss, Misses Revenue Estimates

Mar -26

Source: zacks.com

Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results

Mar -26

Source: businesswire.com

Rockwell Medical to Release Fourth Quarter and Full-Year 2025 Results on Thursday, March 26, 2026

Feb -26

Source: businesswire.com

Rockwell Medical Named 'Great Place to Work' for Fourth Year in a Row

Feb -12

Source: businesswire.com

Analyzing Rockwell Medical (NASDAQ:RMTI) & Senestech (NASDAQ:SNES)

Feb -08

Source: defenseworld.net

Rockwell Medical (RMTI) Upgraded to Buy: Here's What You Should Know

Jan -28

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (12.10%)

6. Segments

Concentrate Products

Expected Growth: 12%

Rockwell Medical's Concentrate Products segment growth is driven by increasing demand for iron therapy, expanding dialysis patient base, and growing adoption of Triferic, a proprietary iron delivery system. Additionally, strategic partnerships, geographic expansion, and favorable reimbursement policies contribute to the 12% growth rate.

Drug

Expected Growth: 16%

Rockwell Medical's 16% growth driven by increasing demand for its flagship drug, Triferic, which treats iron deficiency anemia in dialysis patients. Strong sales momentum, expanded distribution channels, and growing adoption in the dialysis market contribute to the growth. Additionally, the company's focus on research and development, as well as strategic partnerships, position it for continued growth in the pharmaceutical industry.

7. Detailed Products

Triferic

Triferic is an iron replacement and hemoglobin maintenance therapy for patients with hemodialysis-dependent chronic kidney disease (CKD).

Calcitriol

Calcitriol is a vitamin D analog used to treat secondary hyperparathyroidism in patients with CKD.

Dialysate Triferic

Dialysate Triferic is a proprietary formulation of iron delivered during hemodialysis, designed to maintain hemoglobin levels and reduce the need for ESA therapy.

8. Rockwell Medical, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Rockwell Medical, Inc. faces moderate threat from substitutes, as patients may opt for alternative treatments or medications for their iron deficiency anemia. However, the company's innovative products and strong brand recognition help mitigate this threat.

Bargaining Power Of Customers

Rockwell Medical, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are often reimbursed by insurance providers, further reducing customer bargaining power.

Bargaining Power Of Suppliers

Rockwell Medical, Inc. relies on a few key suppliers for raw materials and manufacturing services. While the company has some bargaining power due to its size and reputation, suppliers may still exert some pressure on prices and delivery terms.

Threat Of New Entrants

The pharmaceutical industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and established distribution networks. These barriers make it difficult for new entrants to compete with Rockwell Medical, Inc.

Intensity Of Rivalry

The pharmaceutical industry is highly competitive, with many established players vying for market share. Rockwell Medical, Inc. faces intense competition from companies like Amgen, Pfizer, and Novartis, which may lead to pricing pressure and increased marketing expenses.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	32.98%
Debt Cost	9.96%
Equity Weight	67.02%
Equity Cost	9.96%
WACC	9.96%
Leverage	49.20%

11. Quality Control: Rockwell Medical, Inc. passed 5 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Eagle Pharma

A-Score: 4.5/10

Value: 10.0

Growth: 1.8

Quality: 8.3

Yield: 0.0

Momentum: 7.0

Volatility: 0.0

1-Year Total Return ->

TherapeuticsMD

A-Score: 4.3/10

Value: 6.8

Growth: 4.8

Quality: 4.8

Yield: 0.0

Momentum: 8.5

Volatility: 1.0

1-Year Total Return ->

Organogenesis Holdings

A-Score: 4.1/10

Value: 5.9

Growth: 3.9

Quality: 5.7

Yield: 0.0

Momentum: 8.5

Volatility: 0.7

1-Year Total Return ->

Cyclo Therapeutics

A-Score: 4.0/10

Value: 8.0

Growth: 3.4

Quality: 5.0

Yield: 0.0

Momentum: 6.5

Volatility: 1.0

1-Year Total Return ->

Rockwell Medical

A-Score: 3.3/10

Value: 9.6

Growth: 4.2

Quality: 4.4

Yield: 0.0

Momentum: 0.5

Volatility: 1.0

1-Year Total Return ->

Cumberland Pharmaceuticals

A-Score: 3.0/10

Value: 5.8

Growth: 2.2

Quality: 5.2

Yield: 0.0

Momentum: 4.5

Volatility: 0.3

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

-30.00%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

9.96%

Rockwell Medical, Inc. - US7743743004

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on RMTI

1.c. Company Highlights

Weak Momentum

Fairly Valued

Average Growth

Earnings Beats

Revenues Beats

Average Quality

Stable Momentum

Medium Volatility

Strong Momentum

Earnings Miss

Revenues Miss

Lower Quality

Cheaper

2. Rockwell Medical 2025: Turning Volatility into Profitability

Revenue Dynamics

Gross Margin Expansion

Adjusted EBITDA Resurgence

Cash Flow and Liquidity

Customer Portfolio Strength

At‑Home Dialysis Opportunity

Forward‑Looking Outlook

Valuation Snapshot

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (12.10%)

6. Segments

Concentrate Products

Expected Growth: 12%

Drug

Expected Growth: 16%

7. Detailed Products

Triferic

Calcitriol

Dialysate Triferic

8. Rockwell Medical, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Rockwell Medical, Inc. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

244.38$

Current Price

0.93$

Potential

26265.32%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA